Nanomedicine and Pharmaceutical Nanotechnology

Biography

Dr. Xing-Jie Liang got Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and a principal investigator at Laboratory of Controllable Nanopharmaceuticals, CAS Center for Excellence in Nanoscience and National Center for Nanoscience and Technology of China. Dr. Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, American Society of Cell Biology, American Chemical Society, and deputy director of nanoscale biomaterials committees of Chinese Society of Biomaterials and Chinese Society of Micro/Nanoscale Sicene and Technology.

Research Interest

His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vitro and in vivo, and novel strategies to increase therapeutic effect on cancers and infective diseases. Developing drug delivery strategies for prevention/treatment of infective diseases and cancers are current programs ongoing in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanomedicine. Most protocols are employed for delivering therapeutic molecules (chemical compounds, peptides or nucleic acids) to actively target cells or tissues in vivo to enhance drug safety and efficacy.